Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

<h4>Background</h4>Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and j...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Richard J Perrin, Rebecca Craig-Schapiro, James P Malone, Aarti R Shah, Petra Gilmore, Alan E Davis, Catherine M Roe, Elaine R Peskind, Ge Li, Douglas R Galasko, Christopher M Clark, Joseph F Quinn, Jeffrey A Kaye, John C Morris, David M Holtzman, R Reid Townsend, Anne M Fagan
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2011
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/14913627f3684daeb666751f635a0bc9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/14913627f3684daeb666751f635a0bc9

Ejemplares similares